UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Current oncology reports, 2018-09, Vol.20 (9), p.70-10, Article 70

2018

Volltextzugriff (PDF)

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Cancers, 2019-09, Vol.11 (9), p.1381

2019

Volltextzugriff (PDF)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

International journal of biological sciences, 2019-01, Vol.15 (12), p.2607-2614

2019

Volltextzugriff (PDF)

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC

Translational lung cancer research, 2018-12, Vol.7 (5), p.691-702

2018

Volltextzugriff (PDF)

The combination of checkpoint immunotherapy and targeted therapy in cancer

Annals of translational medicine, 2017-10, Vol.5 (19), p.388-388

2017

Volltextzugriff (PDF)

EGFR first- and second-generation TKIs-there is still place for them in EGFR -mutant NSCLC patients

Translational cancer research, 2019-01, Vol.8 (Suppl 1), p.S23-S47

2019

Volltextzugriff (PDF)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives

OncoTargets and therapy, 2019-06, Vol.12, p.4567-4575

2019

Volltextzugriff (PDF)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Cancers, 2020-06, Vol.12 (6), p.1475

2020

Volltextzugriff (PDF)

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-02, Vol.14 (2), p.304-310

2019

Volltextzugriff (PDF)

Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Current oncology reports, 2020-05, Vol.22 (5), p.52-52, Article 52

2020

Volltextzugriff (PDF)

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Expert review of respiratory medicine, 2019-10, Vol.13 (10), p.1019-1028

2019

Volltextzugriff (PDF)

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma

Annals of translational medicine, 2019-11, Vol.7 (22), p.651-651

2019

Volltextzugriff (PDF)

ARID1A Gene Driver Mutations in Lung Adenocarcinomas

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.e255-e257

2018

Volltextzugriff (PDF)

PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

Journal of cancer metastasis and treatment, 2019-03, Vol.2019

2019

Volltextzugriff (PDF)

Abstract 760: miRNA and mRNA detection in plasma-derived extracellular vesicles (EVs) using the nCounter NanoString platform

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.760-760

2020

Volltextzugriff (PDF)

Abstract 4294: An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4294-4294

2020

Volltextzugriff (PDF)

Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer

Clinical lung cancer, 2019-05, Vol.20 (3), p.167-177

2019

Volltextzugriff (PDF)

Abstract 409: A pre-treatment plasma extracellular vesicle-mRNA signature associates with checkpoint inhibitor pneumonitis in lung cancer patients

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.409-409

2021

Volltextzugriff (PDF)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

EBioMedicine, 2019-01, Vol.39, p.207-214

2019

Volltextzugriff (PDF)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

Translational lung cancer research, 2020-10, Vol.9 (5), p.1810-1821

2020

Volltextzugriff (PDF)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)Research in context

EBioMedicine, 2019-01, Vol.39, p.207-214

2019

Volltextzugriff (PDF)

Osimertinib and Dihydroartemisinin: A Novel Drug Combination Targeting Head and Neck Squamous Cell Carcinoma

SSRN Electronic Journal

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC

The combination of checkpoint immunotherapy and targeted therapy in cancer

EGFR first- and second-generation TKIs-there is still place for them in EGFR -mutant NSCLC patients

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis

ARID1A Gene Driver Mutations in Lung Adenocarcinomas

PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

Abstract 760: miRNA and mRNA detection in plasma-derived extracellular vesicles (EVs) using the nCounter NanoString platform

Abstract 4294: An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood

Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer

Abstract 409: A pre-treatment plasma extracellular vesicle-mRNA signature associates with checkpoint inhibitor pneumonitis in lung cancer patients

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

Abstract 929: Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)Research in context

Osimertinib and Dihydroartemisinin: A Novel Drug Combination Targeting Head and Neck Squamous Cell Carcinoma

Suchergebnisse filtern